LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
LISATA THERAP.INC.DL-001 (8NE) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LISATA THERAP.INC.DL-001 - Net Assets Trend (None–None)
This chart illustrates how LISATA THERAP.INC.DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LISATA THERAP.INC.DL-001 (None–None)
The table below shows the annual net assets of LISATA THERAP.INC.DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LISATA THERAP.INC.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LISATA THERAP.INC.DL-001 Competitors by Market Cap
The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TacBright Optronics Corporation
TWO:6434
|
$17.00 Million |
|
Eva Live Inc. Common Stock
OTCQB:GOAI
|
$17.01 Million |
|
GRODNO S.A. ZY-10
F:WO7
|
$17.01 Million |
|
GO Element Co. Ltd.
KQ:311320
|
$17.02 Million |
|
Leading Edge Materials Corp
OTCQB:LEMIF
|
$17.00 Million |
|
Lam Son Sugar JSC
VN:LSS
|
$16.99 Million |
|
Sungmoon Elect
KO:014910
|
$16.98 Million |
|
Balco Group AB
ST:BALCO
|
$16.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LISATA THERAP.INC.DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LISATA THERAP.INC.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LISATA THERAP.INC.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LISATA THERAP.INC.DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LISATA THERAP.INC.DL-001 (8NE) | €- | N/A | N/A | $17.00 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |